Back

Initial experience with tocilizumab in patients with chronic refractory antibody-mediated rejection: a single center study.

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment (3) Heart Transplantation HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Santiago Fernandez-Gordon Sanchez

UNIVERSITY HOSPITAL VIRGEN DEL ROCIO, Seville (Spain)

5 More presentations in this session

Presentation thumbnail
Longer neurologic death-to-transplant time associated with poor cardiac transplant outcomes
Doctor D. Li (London, CA)
Abstract Slides Video
Presentation thumbnail
Heart transplant in acutely ill patients: time on waiting list and 1-year mortality
Doctor A. Bello (Carnaxide, PT)
Abstract Slides Video
Presentation thumbnail
Analysis of body composition in pre- and post-heart transplant patients
Assistant Professor M. Bohdan (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Do preoperative factors influence cardiopulmonary bypass time and outweigh postoperative care after HeartMate 3 implantation?
Mr D. Verikas (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Diagnostic yield and safety of endomyocardial biopsy in the detection of acute rejection in heart transplant patients: five years of a novel heart transplant program
Doctor M. Casares Ruiz (Las Palmas de Gran Canaria, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment (3)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Optimizing the treatment of acute cardiac rejection: combination therapy of ECMO, plasmapheresis and immunoglobulin, a promising approach for humoral and cellular cardiac recovery
thumbnail
Congress Presentation
Circumferential sub-epicardial LGE as a marker of antibody-mediated cardiac rejection in patients post heart transplantation- CMR as a guide through the storm
thumbnail
Congress Presentation
Efficacy and safety of monoclonal antibodies targeting interleukin-5 and interleukin-4/13 pathways in eosinophilic myocarditis: a single-center experience.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources